검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | KYV-101 (KYV-101, Biological, KYV-101 (Biological) - 1 ×10^8 cells) Bruce Cree·Progressive Multiple Sclerosis 30% |
|---|---|
Overview Program | KYV-101 (Biological) - 1 ×10^8 cells |
Overview Company | Bruce Cree |
Overview Modality | CGT |
Overview Target | Progressive Multiple Sclerosis |
Overview Indication | Progressive Multiple Sclerosis |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | involves modulation of the Notch1 signaling pathway |
MoA Biomarker | EGFR inhibition was down-regulation of MGMT expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Development and biodistribution of 131 I-radiolabeled silver-doped indium oxide nanoparticles as a novel nanoplatform for tumor targeting in tumor bearing mice.. Cancer remains a leading global cause of mortality, with approximately 20 million new cases and 9.7 million deaths reported in 2022. Traditional treatments, including chemotherapy and external beam radiotherapy, are often limited by non-s… |
Toxicology CRS | Reported |
Clinical Primary efficacy | 30% |
Clinical OS | 16.67 |
Clinical Result source | ClinicalTrials.gov NCT02782546 |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | KYV-101 (KYV-101, Biological, KYV-101 (Biological) - 1 ×10^8 cells) Bruce Cree·Progressive Multiple Sclerosis 30% |
|---|---|
Overview Program | KYV-101 (Biological) - 1 ×10^8 cells |
Overview Company | Bruce Cree |
Overview Modality | CGT |
Overview Target | Progressive Multiple Sclerosis |
Overview Indication | Progressive Multiple Sclerosis |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | involves modulation of the Notch1 signaling pathway |
MoA Biomarker | EGFR inhibition was down-regulation of MGMT expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Development and biodistribution of 131 I-radiolabeled silver-doped indium oxide nanoparticles as a novel nanoplatform for tumor targeting in tumor bearing mice.. Cancer remains a leading global cause of mortality, with approximately 20 million new cases and 9.7 million deaths reported in 2022. Traditional treatments, including chemotherapy and external beam radiotherapy, are often limited by non-s… |
Toxicology CRS | Reported |
Clinical Primary efficacy | 30% |
Clinical OS | 16.67 |
Clinical Result source | ClinicalTrials.gov NCT02782546 |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교